Table 4.
Association of cumulative TyG index with CVD-sensitivity analysis
| Analysis 1 | Analysis 2 | Analysis 3 | Analysis 4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CVD | MI | Stoke | CVD | MI | Stoke | CVD | MI | Stoke | CVD | MI | Stoke | |
| Quartiles | ||||||||||||
| Q1 | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
| Q2 | 1.26 (1.07–1.49) | 1.49 (0.99–2.23) | 1.23 (1.02–1.47) | 1.29 (1.11–1.50) | 1.53 (1.07–2.19) | 1.22 (1.03–1.43) | 1.30 (1.12–1.52) | 1.35 (0.95–1.92) | 1.24 (1.05–1.47) | 1.20 (1.04–1.40) | 1.38 (0.98–1.96) | 1.16 (0.99–1.36) |
| Q3 | 1.20 (1.02–1.42) | 1.19 (0.79–1.80) | 1.21 (1.01–1.44) | 1.27 (1.09–1.47) | 1.31 (0.91–1.88) | 1.21 (1.03–1.42) | 1.27 (1.09–1.48) | 1.07 (0.74–1.54) | 1.23 (1.04–1.45) | 1.14 (0.99–1.33) | 1.12 (0.78–1.60) | 1.14 (0.94–1.34) |
| Q4 | 1.35 (1.15–1.59) | 1.34 (0.89–2.02) | 1.36 (1.14–1.63) | 1.43 (1.23–1.66) | 1.60 (1.11–2.29) | 1.33 (1.13–1.57) | 1.52 (1.31–1.77) | 1.34 (0.94–1.91) | 1.40 (1.19–1.66) | 1.25 (1.06–1.46) | 1.24 (0.85–1.80) | 1.24 (1.04–1.47) |
| Time exposure duration | ||||||||||||
| 0 year | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | – | – | – |
| 2 years | 1.28 (1.12–1.47) | 1.46 (1.04–2.04) | 1.26 (1.09–1.45) | 1.22 (1.07–1.38) | 1.51 (1.13–2.01) | 1.16 (1.01–1.33) | 1.24 (1.09–1.41) | 1.51 (1.13–2.02) | 1.20 (1.05–1.38) | – | – | – |
| 4 years | 1.26 (1.08–1.48) | 1.22 (0.81–1.85) | 1.27 (1.06–1.51) | 1.23 (1.06–1.43) | 1.24 (0.86–1.79) | 1.23 (1.01–1.45) | 1.19 (1.02–1.39) | 1.21 (0.84–1.74) | 1.19 (1.01–1.40) | – | – | – |
| 6 years | 1.24 (1.04–1.48) | 1.54 (1.01–2.34) | 1.18 (0.96–1.43) | 1.10 (0.92–1.31) | 1.32 (0.88–1.97) | 1.05 (0.86–1.28) | 1.18 (0.99–1.39) | 1.26 (0.85–1.87) | 1.15 (0.95–1.38) | – | – | – |
| 8 years | 1.51 (1.26–1.79) | 2.08 (1.39–3.10) | 1.42 (1.17–1.72) | 1.42 (1.20–1.69) | 2.11 (1.46–3.03) | 1.29 (1.06–1.57) | 1.46 (1.24–1.71) | 1.78 (1.23–2.57) | 1.37 (1.15–1.65) | – | – | – |
Multivariable model adjusted for sex, income, educational level, drinking, smoking, diabetes, hypertension, lipid‐lowering medication, BMI, RHR, HDL-C, LDL-C, UA, Hs-CRP
Analysis1 excluded participants events occurring in the first 2 years of follow-up (n = 884); Analysis2 excluded participants with diabetes at baseline (n = 3320); Analysis3 excluded received treatment with lipid lowering medication at baseline and follow-up (n = 5866); Analysis4 additional adjustment for TyG index at baseline